Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon for Jet Lag Disorder (Phase 3)
2015-003198-14Phase 3Terminated
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in jet lag disorder comparing Tasimelteon 20 mg with Placebo (2 arms). Primary endpoint: Total Sleep Time in first two thirds of the night (TST2/3) on the worst of 3 nights. Started Oct 2015; status: terminated.
02
Drugs
tasimelteon
03
Conditions
jet lag disorder
Beyond the preview
Go deeper on 2015-003198-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003198-14.